Document is current
Any future updates will be listed below
-
Authors
Klussmann, Jens Peter
Grosheva, Maria
Meiser, Peter
Lehmann, Clara
Nagy, Eszter
Szijártó, Valéria
Nagy, Gábor
Konrat, Robert
Flegel, Michael
Holzer, Frank
Groß, Dorothea
Steinmetz, Charlotte
Scherer, Barbara
Gruell, Henning
Schlotz, Maike
Klein, Florian
de Aragão, Paula Aguiar
Morr, Henning
Al Saleh, Helal
Bilstein, Andreas
Russo, Belisa
Müller-Scholtz, Susanne
Acikel, Cengizhan
Sahin, Hacer
Werkhäuser, Nina
Allekotte, Silke
Mösges, Ralph
-
Funding
Funding for this research was provided by:
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 25 July 2022
Accepted: 29 March 2023
First Online: 26 April 2023
Competing interests
: JPK and CL have received grants from the sponsor URSAPHARM Arzneimittel GmbH for performing this trial. EN, VS and GN are shareholders in CEBINA GmbH, RK and EN are inventors on related patent applications. PM, MF, DG, CS and BS are employed at URSAPHARM Arzneimittel GmbH. FH is the CEO of URSAPHARM Arzneimittel GmbH. BR, SMS, HS, CA, NW, SA, and RM are employees of ClinCompetence Cologne, the CRO which organized this trial. HG, MS, and FK declare no conflict of interest. MG, PA, HM and HAS declare no conflict of interest. AB is employed at Ursatec GmbH, supplier of primary packing materials to Ursapharm.
